Stem bromelain [EC 3.4.22.32] is a thiol-endopeptidase and orally recommended in traditional medicine due to its analgesic activity, but the mechanisms are not known. Proenkephalin is expressed in the nervous system, but also in the gastrointestinal tract, where it can be assessed by ingested stem bromelain. Here we demonstrated that stem bromelain hydrolyses synthetic proenkephalin fragments after basic amino acid residues flanking the enkephalin sequences. We also observed with in vivo studies that oral administration of bromelain reduced jejunum proenkephalin levels and increased the serum enkephalin in mice. Effective anti-nociceptive effects in mice were observed 3 h after oral administration of 3 mg/kg stem bromelain by the acetic acid-induced writhing test. However, with higher doses this effect is reduced due to hydrolysis of enkephalin that possibly occurs by the presence of ananain in commercial pineapple stem bromelain preparations, that is also a thiol-protease with broad specificity. The analgesic effects were also evaluated by hot-plate and formalin tests and the obtained results indicated that enkephalin generated in intestine acts in periphery where it also can have anti-inflammatory activity.
Introduction
The stem and fruit pineapple (Ananas comosus) are rich sources of thiol-endopeptidases and they have been referred as stem bromelain and fruit bromelain, respectively. Commercially available stem bromelain is a dried powder prepared from waste pineapple stem material; and the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology adopted its systematic classification as stem bromelain [EC 3.4.22.32] [1]. Pineapple bromelain is used and sold in the commerce for several purposes, including as nutritional supplement all over the world and for a long time and is traditionally recommended for pain and inflammation relief. Stem bromelain applications in several physiopathological processes were reviewed [2, 3] and the analgesic effects of orally ingested stem bromelain have been consistently reported [4] [5] [6] [7] ; however, any convincing mechanism was so far proposed for the pain relief effects of stem bromelain.
At least three different proteases were biochemically characterized as thiol-endopeptidases in pineapple stem and the major component (at least 90%) is referred as stem bromelain, and the other two are ananain and comosain [8] [9] [10] . Stem bromelain has a very efficient peptidase activity on synthetic fluorescent dipeptide Z-R-R-MCA with releasing of MCA (methyl-7-aminocoumarin amide), the fluorescent group and Z-R-R-OH (Z = carbobenzoxy group and R = arginine) [9] . This preference of stem bromelain to cleave substrates after a pair of basic amino acids was confirmed by the assays of combinatorial peptide library [11] and by solution-phase fluorogenic peptide microarrays [12] . This substrate specificity of stem bromelain cleaving after a pair of basic amino acids reminds those of the central nervous system prohormone convertases 1 and 2 (PC1 and PC2) to generate enkephalin from proenkephalin (PENK) cleaving this protein and synthetic peptides derived from it specifically and exclusively after pairs of basic amino acid residues KR, KK and RR (K = lysin) [13] [14] [15] [16] [17] ; for review [18, 19] . The cleavage of PENK by PC1 and PC2 generates enkephalin containing at its C-terminal end a pair of basic amino acids that requires a carboxypeptidase to produce opioid-active enkephalins, as carboxypeptidase E [20] carboxypeptidase D [21] or carboxypeptidase M [22] .
It is well demonstrated that proenkephalin (PENK) is expressed in the neuronal tissue but it is also present in the gastrointestinal tract [23] [24] [25] . The mouse as well as human PENK contain seven enkephalin sequences flanked by pairs of basic amino acid residues (KR, KK and RR) and are sites potentially susceptible to hydrolysis by stem bromelain that could mimic the activities of PC1 and PC2.
In the present study, we sought to evaluate whether synthetic PENKderived peptides containing enkephalin sequences are hydrolyzed by stem bromelain releasing enkephalin precursors as we previously observed with PC2 [17] . The enkephalins released from PENK modulate pain through autocrine or paracrine pathways [26, 27] , then we assessed the potential analgesic effect of orally ingested stem bromelain through in vivo experiments using acetic acid-induced writhing test, hot-plate and formalin tests. PENK in jejunum sections was also monitored by immunofluorescence assays and enzyme immunoassay was used for detecting the serum levels of enkephalin.
Materials and methods

Stem bromelain
All experiments were performed with commercial stem bromelain (Sigma; catalog number B-4882; lot #80K1406), carrying an enzymatic activity of 3.5 U/mg. According to the manufacture, one unit will release 1.0 μmole of p-nitrophenol from N-α-Z-L-lysine p-nitrophenyl ester per min at pH 4.6, 25°C.
Peptide synthesis
Peptides were obtained by solid-phase synthesis, using the Fmoc (N-(9-fluorenyl)-methoxycarbonyl) methodology, on an automated multiple peptide synthesizer (PSSM-8 system; Shimadzu, Tokyo, Japan), as previously described [28, 29] . Synthesis were carried out on a NovaSyn ® TGR resin (Millipore, USA), using HBTU (N,N'-tetramethyl-O-benzotriazo-1-yluronium tetrafluoroborate)/HOBt (1-hydroxybenzotriazole) as coupling reagent. The removal of peptide from the resin was accomplished with TFA:thioanisole:1,2-ethanedithiol:water (85:5:3:7). Peptides were purified by semi-preparative HPLC on a C18 column (Econosil ™ ; Fisher Scientific, USA) and their molecular weight and purity (> 95%) checked by reverse-phase chromatography and by mass spectrometry (Shimadzu, Japan).
Stem bromelain processed peptides
Synthetic mouse PENK-derived peptides were obtained by solid phase peptide synthesis as fluorescence resonance energy transfer (FRET) peptides [29] . The essential feature of this procedure is the synthesis of an Nα-Boc or Nα -Fmoc derivative of glutamic acid with the α-carboxyl group bound to N-(2,4-dinitrophenyl)-ethylenediamine (EDDnp), which provides the quencher moiety attached to the C-terminus of the peptide. The fluorescent donor group, ortho-aminobenzoic acid (Abz), is incorporated into the resin-bound peptide in the last coupling cycle. The following FRET peptide sequences were synthesized and assayed: (a) Abz-LLAKKYGGFMKRYGGFMKKMD-EDDnp; (b) Abz-DMSKRYGGFMRSLKRSP-EDDnp; (c) Abz-ELQKRYGGFMRRV-GRP-EDDnp; (d) Abz-DYQKRYGGFLKRFAESL-EDDnp; and (e) Abz-VPEIEKRYGGFMRF-EDDnp. Peptides were incubated with 20 μg/ mL or 1 mg/mL stem bromelain for increasing periods of time (2 min till 12 h). Reactions were carried out on 20 mM Tris, 1 mM EDTA, pH 7.5. After incubation, proteolytic activity was terminated with 10% TFA. Cleavage products of the Abz-peptidyl-Q-EDDnp peptides were detected by their UV absorption at 220 nm and the molecular weight was determined by LC/MS using an LCMS-2010 equipped with an ESI-probe (Shimadzu, Japan) connected to the HPLC effluent after the UV detector. The fluorescence changes due to peptide hydrolysis were measured at λ ex = 320 nm and λ em = 420 nm. The HPLC conditions were: Ultrasphere C-18 column (5 μm, 4.6 x 250 mm) eluted with solvent systems A (H 3 PO 4 /water, 1:1000) and B (ACN/water/ H 3 PO 4 , 900:100:1) at a flow rate of 0.8 mL/min and a 0-80% gradient of solvent B for 60 min.
Animals
Male Balb/c (20-25 g) or Swiss (25-35 g) mice were obtained from Instituto de Farmacologia e Biologia Molecular (INFAR, Sao Paulo, Brazil) animal facility. For antibody production, male white New Zealand rabbits (3-6-week-old) were obtained from Universidade Federal do Rio Grande do Sul animal facility. Animals were maintained with a 12:12 h light: dark cycle and water ad libitum. At the end of the experiments, mice were euthanized by cervical dislocation under anesthesia with ketamine (80 mg/kg; Syntec, São Paulo, SP, Brazil) and xylazine (20 mg/kg; Syntec, Brazil). The rabbits were euthanized under anesthesia with intraperitoneal thiopental 100 mg/kg. All procedures, approved by the local experimental ethics committee (Protocol numbers 262/CEUA, 24651/CEUA UFRGS and 23080.035334/2009-18/ UNIFESP), were in accordance with the guidelines of the US National Research Council for care and use of laboratory animals (NRCC, 2011) [30] . Animals were randomly divided into the experimental groups and the investigator was blinded to the group allocation. Sample size was chosen based on previous experiments in our laboratory.
Treatment schedule
Mice were treated by gavage with stem bromelain in tap water, or with the vehicle alone, as a control. Treatment doses of stem bromelain ranged from 0.1 to 300 mg/kg and are presented together with the results. Assays were performed 1 to 8 h after treatment, as indicated. All animals were fasted for 6 h prior to oral treatment.
To evaluate the PENK expression in intestinal tissue, 4 and 8 h after stem bromelain administration (300 mg/kg), mice were euthanized. Jejunum fragments were removed and frozen in optimum cutting temperature medium for further immunofluorescence analysis. Mice were anesthetized with ketamine (80 mg/kg; Syntec, Brazil) and xylazine (20 mg/kg; Syntec, Brazil) for blood collection before and after stem bromelain treatment.
Acetic acid writhing test
Acetic acid-induced writhing test was performed as previously reported [31] with minor modifications [32] , using mice injected intraperitoneally with 0.6% acetic acid (1% v/v; 0.1 mL/10 g). After the challenge, mice were individually placed into a 20 cm-diameter cylindrical glass chamber and the number of abdominal constrictions (i.e., writhes) was recorded over a period of 20 min. Anti-nociceptive activity was expressed in the number of writhes.
To obtain the time-course response, mice received orally 10 mg/kg stem bromelain (dose used in preliminary assays) and the writhing test was performed at 0, 1, 2, 3, 4, 6 and 8 h post-administration. Groups of 10-15 mice, as indicated in figure legends, were used for each group. On the other hand, to access the dose-response curve, experiments were conducted 3 h after mice receiving stem bromelain doses varying from 0.1 to 300 mg/kg (n = 10-30, as indicated in figure legends) . The specificity of proteolytic activity of stem bromelain associated to the anti-nociceptive effects was evaluated in assays with mice treated with stem bromelain completely inhibited by E-64 (trans-Epoxysuccinyl-Lleucylamido(4-guanidino) butane) (Sigma-Aldrich, USA). Groups receiving 2 μM/kg E-64 or vehicle were used as controls. The number of acetic acid-induced abdominal constrictions was also assessed in groups of 10-15 mice, as indicated in figure legend, treated with the other proteolytic enzymes: 10 mg/kg papain (Sigma-Aldrich, USA) and 10 mg/kg arazyme, obtained as previously reported [33] . All these assays were conducted 3 h after oral administrations and were replicated 3 times.
Hot-plate test
The hot-plate test was performed according to the procedure previously reported [34] . Briefly, the animals were placed into a 24-cm diameter glass cylinder on a heated surface (55 ± 1°C) and the time between placement and the initial response to the painful stimulus (elevation, shaking or licking of the paws or jumping) was recorded as the response latency. All animals were selected 2 h previously the assays based on their reactivity in the test by eliminating those that remained on the apparatus for up to 8 s. To minimize damage to the animal paws, the cut-off time was 30 s and defined as complete antinociception.
Formalin test
The formalin test was used to evaluate chemical nociception of stem bromelain. The procedure employed was like that previously described [35, 36] . Briefly, animals received 20 μL of 2.5% formalin (0.92% formaldehyde; LabSynth, Brazil) under the ventral surface of the right hind paw. Animals received vehicle, stem bromelain (3 mg/kg; SigmaAldrich, USA), morphine (20 mg/Kg; Merck, Germany) or acetylsalicylic acid (100 mg/Kg; LabSynth, Brazil) 3 h before the assays. After the intraplantar injection of formalin, each animal was immediately placed into a transparent glass cage and had the time spent licking the injected paw recorded and considered as an indicative of nociception. This model provided evidence of two phases of painful sensitivity: an immediate early phase, in the first 5 min (pain of neurogenic origin), and a late phase, from 15 to 30 min (pain of inflammatory origin), after the injection of formalin [36] .
Immunofluorescence staining
Jejunum cryosections (7 μm thickness) were fixed in ethanol 70% for 10 min and permeabilized with TBS/0.5% (w/v) saponin. Slices were blocked with 8% (w/v) BSA (Sigma-Aldrich, USA) in TBS overnight at 4°C and were further incubated with rabbit anti-PENK antiserum, diluted 1:100 in blocking buffer, for 1 h at 37°C. Primary antibodies were detected using 1:200-diluted Alexa Fluor® 488-conjugated anti-rabbit secondary antibodies (Life Technologies, USA). All steps were followed by washing three times with TBS. Negative control was achieved by pre-immune serum incubation. Nuclei were stained with DAPI. Images were captured on a Leica TCS SP8 microscope (Leica; Wetzlar, Germany) with a 40x objective. Quantification of PENK-positive cells was performed on 10 independent fields per tissue section, using ImageJ software (NIH, USA).
Production of polyclonal antisera
PENK-95-116 peptide (sequence in Fig. 1A ) was obtained by solid phase peptide synthesis purified by HPLC and characterized as showed in and Fig. 1B . Polyclonal antiserum was obtained by rabbit immunization against the PENK-95-116 peptide. For that, rabbit was immunized subcutaneously with 1 mg KLH-conjugated PENK-95-116 peptide emulsified with Montanide (Seppic) 888/Marcol 52 oil adjuvant (Exxon Mobil Corporation). After three inoculations with twoweek intervals, the animal was bled, and serum titer was checked by ELISA. Antibody reactivity was certified by immunolabeling assays Fig. 1C . As depicted in Fig. 1D ,˜37-kDa and˜15-kDa bands were detected in jejunum extracts through antiserum polyclonal-stained immunoblots. Also, this antibody was shown to bind only to its immunogen, not reacting with other PENK enkephalin-containing sequences (Fig. 2) .
Enzyme immunoassay (ELISA) binding studies
Enzyme immunoassays (ELISA) studies were used to access the proenkephalin (PENK) antiserum reactivity to the immunizing peptide and for detecting stem bromelain and Met-enkephalin in mouse serum samples. Experimental procedures are described below. The assays were revealed with 3,3′,5,5′-tetramethylbenzidine (TMB; Zymed, USA). All steps were followed by washing three times with TBS/0.1% (v/v) Tween-20. The reaction was stopped with sulfuric acid solution and optical density (OD) was measured at 450 nm. Studies were carried out in duplicate.
Evaluation of PENK antiserum reactivity
96-well plates were coated with the PENK-95-116 peptide in TBS (50 mM Tris, 150 mM NaCl, pH 7.5). Plates were blocked with 1% (w/ v) bovine serum albumin (BSA; Sigma-Aldrich, USA) in TBS and, then, incubated with two-fold serial dilution of the screening antiserum (or pre-immune serum, as a control) for 2 h at 37°C. Then, plates were incubated with biotin-labeled anti-rabbit secondary antibody (SigmaAldrich, USA) and horseradish peroxidase-streptavidin (Sigma-Aldrich, USA).
Detection of stem bromelain in serum samples
The stem bromelain detection in mouse serum samples was achieved by a competitive inhibition ELISA. For that, 96-well plates were coated with stem bromelain (Sigma-Aldrich; catalog #B4882; lot #80K1406, USA) in TBS (50 mM Tris, 150 mM NaCl, pH 7.5). Plates were blocked with 1% BSA in TBS and, then, overnight incubated at 4°C with 1:1-diluted sera samples in the presence of 1 μg/mL anti-stembromelain antibody (MyBioSource; catalog #MBS6009894). The antigen-antibody binding was detected using biotin-labeled anti-rabbit secondary antibody (Sigma-Aldrich, USA), followed by horseradish peroxidase-streptavidin (Sigma-Aldrich, USA). The lower limit of detection with this assay was approximately 30 ng/mL of stem bromelain.
Detection of enkephalin in serum samples
A competitive inhibition enzyme immunoassay was used for detecting the serum levels of enkephalin. The assay was conducted using a commercial ELISA kit (MyBioSource; catalog #MBS756178), according to the manufacturer's instruction, with the detection limit of 1 pg/mL. For that, pre-coated plates were incubated for 1 h at 37°C with 1:5-diluted sera samples in the presence of an HRP-conjugated anti-enkephalin antibody solution.
Immunoblotting
Antiserum immunoreactivity was evaluated on jejunum protein extracts separated on 12% SDS-polyacrylamide gels, under reducing conditions, and further transferred to polyvinylidine difluoride membranes (Millipore, Billerica, MA, USA). After blocking with 8% (w/v) BSA in TBS/0.1% (v/v) Tween-20, membranes were probed with 1:100-diluted antiserum. Extracts were obtained using lysis buffer [50 mM Tris, pH 8.0, 150 mM NaCl, 0.5% (v/v) Triton X-100, 10% (v/v) glycerol, 1 mM DTT, and protease inhibitors] and its protein content was measured by Bradford colorimetric method (Thermo Scientific, USA). Membrane-bound primary antibodies were detected using HRP-conjugated anti-rabbit secondary antibodies, further revealed by chemiluminescence (Thermo Scientific, USA).
Clotting assays
Prothrombin time (PT) and activated partial thromboplastin time (aPTT) of plasma samples were measured with a fibrometer (BFT II Analyzer; Siemens, Germany). For aPTT test, plasma samples and aPTT reagent (Pathromtin ® SL; Siemens, Germany) were mixed and incubated at 37°C for 2 min before addition of 50 μL of 25 mM CaCl 2 and measurement of the clotting time. In PT clotting measurements, the thromboplastin reagent (Thromborel ® S, catalog #OUHP29; Siemens, Germany) was added to 37°C-heated plasma samples. Experiments were conducted within 2 h following blood collection to minimize 
Statistical analysis
Pharmacological data are reported as mean ± SD of at least 8 animals. Statistical differences between groups were evaluated with GraphPad Prism (GraphPad Software, La Jolla, CA, USA) using Student's t-test or one-way ANOVA followed by Bonferroni's post-test. P < 0.05 was considered significant.
Results
Stem bromelain hydrolyses synthetic mouse PENK-derived peptides releasing enkephalin precursors
The peptides derived from mouse PENK sequence were prepared as 4) were incubated with 20 μg/mL or 1 mg/mL stem bromelain (details in Methods). All these peptides contain an enkephalin (YGGFM or YGGFL) sequence (Fig. 3A) . The hydrolysis by 20 μg/mL stem bromelain of all peptide sequences occurred after the pairs of basic amino acids, releasing enkephalin precursors containing a pair of basic amino acid at theirs C-terminal ends. However, higher stem bromelain concentration (1 mg/mL) led to complete degradation of all peptides with digestions down to almost free amino acids (Fig. 3B) . The faster hydrolysis determined by HPLC characterization and time of appearance during the incubation of the FRET peptides with stem bromelain are those in R in the pair of basic amino acid residues (RR↓ or KR↓).
Anti-nociceptive activity of stem bromelain
The dose and time after administration that best elicits the antinociceptive response of stem bromelain was examined in the acetic acid-induced writhing test. Within the 1-8 h interval post-administration of stem bromelain (10 mg/kg), the best response was obtained in the 3-h group: inhibition of about 62% in the mean number of writhes was observed, compared to the control group (p < 0.001) (Fig. 4A) . Considering this result, the 3-h time point was chosen in all further experiments. Symptoms such as tremors, hind limb alterations, ataxia, piloerection, convulsion, muscular tonus, posture or loss of reflexes were not observed. Further studies conducted to evaluate the role of stem bromelain doses in the observed anti-nociceptive effects demonstrated a U-shaped dose-response curve. In the 0.1-300 mg/kg range, the best analgesic effect was achieved with 3 mg/kg (mean inhibition in the number of writhes of 68%; p < 0.001 compared to control) (Fig. 4B) . The response of 3 mg/kg of stem bromelain was close to that obtained with 100 mg/Kg of acetylsalicylic acid (ASA), which is the reference for analgesic activity (Fig. 4C) .
The conditions that resulted in the best anti-nociception activity were applied in hot-plate and formalin tests as alternative experimental models of pain. In the hot-plate test, mice treated with 3 mg/kg had reaction times in the limits of significance higher than vehicle-treated animals (p < 0.05; one-way ANOVA), and no difference in latency was detected with higher doses (10 and 100 mg/kg; p > 0.05). Morphine caused the expected increase in the pain latency. Formalin test also yielded meaningful results for stem bromelain (3 mg/kg). An increase in the number of cumulative flinches was detected on the phase 1 (p < 0.01, compared to control) and on phase 2 (p < 0.01, compared to control) of the formalin test. ASA and morphine were used as controls. Details of these results are in Fig. 5 . Fig. 6A shows that stem bromelain inhibited with E-64, a specific and irreversible cysteine protease inhibitor, lost its anti-nociceptive effect (p < 0.01 compared to hydrolytic active stem bromelain), as assessed by acetic acid writhing test. It is also worth noting that the anti-nociceptive effect of stem bromelain is specific, because the analgesic effect was not observed with other proteolytic enzymes as papain, which is a cysteine protease of the same class as stem bromelain but without the same substrate specificity [37, 38] , and arazyme, an exocellular metalloprotease isolated from Serratia proteamaculans culture medium [33] (Fig. 6B) .
Anti-nociceptive effect of stem bromelain depends on its proteolytic activity
Stem bromelain reduced PENK in jejunum and increased enkephalin in serum
PENK levels were monitored in jejunum sections from mice treated with a single oral dose of 300 mg/kg stem bromelain (or its vehicle, as a control). This amount of stem bromelain for the histological analysis, compared to the pharmacological assays, was used because the image sensitivity was not enough to clearly detect variation of PENK with 3 mg/kg stem bromelain treatment. Animals were euthanized 4 and 8 h later and the treatment schedule was the same employed in pharmacological studies. As shown by immunofluorescence assays, stem bromelain reduced PENK in jejunum mucosa (Fig. 7A) up to 8 h after treatment. Cells from the lamina propria, in the core of jejunum villi, also displayed a positive cytoplasmic staining and, curiously, the number of such PENK-positive cells seemed to be reduced under stem ; stem bromelain 10 mg/kg (n = 10); stem bromelain 30 mg/kg (n = 18); stem bromelain 100 mg/kg (n = 10); stem bromelain 300 mg/kg (n = 10). (C) Box-plots show that the writhing response achieved with 3 mg/kg stem bromelain 3 h before acetic acid injection is like the obtained with 500 mg/kg acetylsalicylic acid (ASA). Experimental groups: vehicle (n = 15); stem bromelain 3 mg/kg (n = 10); stem bromelain 10 mg/kg (n = 10); ASA 20 mg/kg (n = 10). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; one-way ANOVA/Bonferroni's post-test. Assay was conducted 3 h after stem bromelain treatment and 1 h after ASA (100 mg/kg) and morphine (20 mg/kg) administration. Treatment groups: vehicle (n = 10); stem bromelain 3 mg/kg (n = 12); ASA (n = 10); morphine (n = 10). *P < 0.05; **P < 0.01; ****P < 0.0001; one-way ANOVA/Bonferroni's post-test. Fig. 6 . Anti-nociceptive effect of stem bromelain is inhibited by the E-64 protease inhibitor. (A) Number of writhing episodes detected in mice receiving orally vehicle (n = 33), 2 μM E-64 (n = 8), 3 mg/kg stem bromelain (n = 29), or 3 mg/kg stem bromelain pre-incubated with 2 μM/kg E-64 (n = 12). (B) Comparison of the number of writhes achieved in mice receiving 3 mg/kg stem bromelain (n = 9) with the obtained under 10 mg/kg arazyme (n = 25) or 10 mg/kg papain (n = 20) treatment. Vehicle (n = 28) was used as a control. Assays were conducted 3 h after oral stem bromelain administration. ***P < 0.001; ****P < 0.0001; one-way ANOVA/Bonferroni's post-test. Experiments were replicated 4 times. Sections from vehicle-treated mice (n = 15) were used as a control. *P < 0.05; **P < 0.01; one-way ANOVA/Bonferroni's post-test. (C) Enkephalin levels, detected by ELISA, in serum samples collected before and 3 h after mice oral treatment with vehicle or 3 mg/kg stem bromelain. Graph on the right displays the ratio (mean ± SD) between enkephalin levels detected after (A) and before (B) treatment in serum samples collected from the same mice (A/B ratio). bromelain treatment (Fig. 7B) . Pre-immune serum was used as a control. These experiments were conducted using a polyclonal antiserum raised against a synthetic PENK (residues 95-116) peptide. Details about the polyclonal antiserum are in Figs. 1 and 2 , in Materials and methods section. Conversely, a competition binding immunoassay revealed increased concentrations of enkephalin in serum samples from mice treated with 3 mg/kg stem bromelain, compared with the vehicle group (Fig. 7C) . It is important to mention that stem bromelain was not detected in serum samples from the stem bromelain-treated mouse group, at least in concentrations higher than 30 ng/mL, as assessed by enzymatic immunoassay (Fig. 8) . Although coagulation is known to be affected by stem bromelain, we did not detect increased blood clotting time (aPTT and PT) in mice treated with stem bromelain (Fig. 9) . These assays were conducted with samples collected 3 h after oral administration of 3 mg/kg stem bromelain.
Discussion
We demonstrated that PENK-derived FRET peptides are hydrolyzed by stem bromelain, producing sequences containing enkephalin followed by basic pairs of amino acid residues. The complete release of enkephalin from the resulting peptides will require the activity of a carboxypeptidase to remove the C-terminal basic amino acids.
Carboxypeptidase M seems to be a more appropriated candidate due to its preference to remove basic residues and its presence in the external surface of cell membrane from many tissues including kidney, lung, placenta and blood vessels [22] .
Stem bromelain has been used in the treatment of several clinical conditions, particularly for pain relief, but so far little was known about the mechanisms of stem bromelain analgesic effect or even about the anti-nociceptive activity of the enzyme. Here, we show that the antinociceptive effect of stem bromelain is dose-and time-dependent, with the best results achieved in mouse at 3 mg/kg, 3 h after oral administration. Higher doses of stem bromelain, instead of leading to improve analgesic effect, revealed minor effects (Fig. 4B ). This unexpected result was also observed in a clinical trial for inducing analgesia after tooth removal surgery. The oral dose of 1000 FIP (Fédération Internationale Pharmaceutique) units, recommended for the marketed Bromelain-POS® product, was found more effective in inducing analgesia after tooth removal surgery than that achieved with higher doses (3000 and 4500 FIP) [39] . The stem bromelain behavior at low concentrations reflects its high specificity to cleave peptide sequences after pairs of basic amino acid residues (Lys-Lys, Lys-Arg or Arg-Arg), as we observed with PENK-derived FRET peptides, and previously reported in stem bromelain specificity studies [9, 11, 12] .
The dose-response curve in a U-shape format, is possibly related to the presence of other thiol-proteases in the crude commercially available stem bromelain, which at low concentration the stem bromelain is prevalent and releases enkephalin precursors but at high concentrations the other thiol-proteases digests the substrates down to free amino acids (Fig. 3) . In fact, commercial stem bromelain contains ananain and comosain, both pertaining to bromelain family. Ananin represent 5% of proteins in pineapple stem extract, and it is the second most abundant peptidase. The substrate specificity of ananain is broder than that of stem bromelain that can produce the unspecific hydrolysis observed with PENK derived FRET peptides (Fig. 3) and be responsible for the lost of analgesic activity when high concentrations of stem bromelain is ingested. Comosain is present in low abundance in pineapple stem and its substrate specificity is like to that of stem bromelain [9] . PENK and its derived products were previously demonstrated to be present in several non-neuronal tissues, which include skeletal muscles and gastrointestinal epithelium [23] [24] [25] , and in the present study, we observed considerable immunofluorescence staining for PENK on jejunum villi and smooth muscle layer. Nonetheless, it is worth considering that stem bromelain was previously shown to be proteolytically active even after being exposed to stomach low pH as well as to pancreatic digestive enzymes [40] ; and stem bromelain active form was detected in the small intestine of mice and pigs following its oral administration [41] [42] [43] .
Stem bromelain is known to be poorly absorbed when administered orally [41, 44] and, indeed, we failed to detect stem bromelain in sera from mice 3 h after oral intake of 3 mg/kg. Although we cannot discard the presence of serum stem bromelain concentrations lower than 30 ng/ mL, due to limitation of the employed assay, an eventual undetectable level might not be adequate for the proteolysis of a significant amount of stem bromelain substrates after the blood access. In fact, stem bromelain concentrations greater than 500 μg/mL are required to surpass the alpha-2-macroglobulin inhibition in the blood [45] .
Taken together, these data demonstrate that the anti-nociceptive effect of orally administered stem bromelain may likely reflect its local proteolytic activity within the jejunum tract, rather than a systemic response. Our assumption concerning the enkephalin release by stem bromelain was further validated by in vivo studies, which revealed that stem bromelain oral treatment led to reduced PENK signal in jejunum mucosa, detected by immunofluorescence assays with a polyclonal antiserum reactive to PENK (residues 95-116), followed by increased serum levels of enkephalin, compared to that obtained with controls.
It is important to note that cells from the lamina propria, in the core of jejunum villi, also displayed a positive cytoplasmic staining for PENK. Although dense-core vesicle storage is characteristic of opioid peptides storage, we cannot rule out the possibility of these PENK-positive cells coming from the immune infiltrate of the mouse intestinal tract, since immune competent cells are one of the major elements of the intestinal lamina propria [46] . Previous reports showed that immunocytes release enkephalins [47] [48] [49] , and such release modulate the intensity of inflammation-related pain [50] . In addition, it is worth noting that stem bromelain treatment has been shown to selectively alter surface molecules on lymphocytes, which may affect the migration and activation status of these cells [45] . These data are compatible with the reduced number of PENK-positive cells detected in the jejunum lamina propria sections from mice under stem bromelain treatment. These are relevant considerations because, recently, stem bromelain has been shown in humans to modulate the cellular responses of lymphocyte after oral use and postulated to be related to the observed antiinflammatory responses [51] .
In our immunofluorescence studies, enkephalin might not be recognized by the employed polyclonal antiserum, since these antibodies do not bind to other enkephalin-containing sequences in addition to the one used for immunization. However, incompletely processed PENKderived peptides may also have contributed to the observed immunoreactivity. The 15-kDa band found in immunoblotting analysis of jejunum extracts indicates that high molecular weight PENK-derived peptides are also recognized by the polyclonal antiserum used. This is in line with other reports describing the detection of high molecular weight proenkephalin-derived species in several tissues [52] [53] [54] . Previous report [53] provides evidence that a 15-kDa band detected in immunoblots might correspond to a PENK (residues 25-140) NH 2 -terminal peptide, which comprises the epitope sequence recognized by the polyclonal antibody. Moreover, the 15-kDa peptide was reported as membrane-bound, being accessible, then, to several components in contact with the tissue, which include stem bromelain. In addition, the novelty of our data about the bromelain analgesia be related to release of enkephalin seems quite well convincing, although further work is necessary to understand the structural mechanisms of bromelain interactions on intestine mucosa. After stem bromelain treatment the inverse correlation between the presence of proenkephalin in jejunum and enkephalin levels in serum is clear although it was qualitatively demonstrated (Fig. 7) .
The level of brain enkephalin we do not expect to be influenced by stem bromelain because the enkephalin is generated in the periphery and will not be able to cross the blood brain barrier [55] . In fact, the data in hot plate test, which involves higher brain function and considered to be a supraspinal organized response [34] , shows less analgesic effect of stem bromelain that was detected only with 3 mg/kg and in the limit of significance.
Conclusion
The present study provide evidence that the cleavage by stem bromelain of the enkephalin precursor molecule in the jejunum gives rise to multiple active endogenous opioid peptides where they are released and absorbed. The jejunal generated enkephalin probably acts in periphery where it also can have anti-inflammatory activity. The observations presented in this report help to elucidate the analgesic and possible anti-inflammatory activities of stem bromelain that has been recognized for many decades. Further biochemical and pharmacological studies are required with pure recombinant bromelains, as recently obtained [56] , in order to clearly understand the effects of the crude commercially available stem bromelain. 
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